Gruszecka Jolanta, Filip Rafał
Institute of Health Sciences, Medical College of Rzeszow University, Rzeszow, Poland.
Department of Clinical Microbiology, Clinical Hospital No. 2, im. Św. Jadwigi Królowej, Rzeszow, Poland.
Gut Pathog. 2021 Dec 13;13(1):73. doi: 10.1186/s13099-021-00471-z.
There are several studies which evaluated the number of infections caused by enteric pathogens, including Clostridioides difficile in patients with inflammatory bowel disease (IBD). Our aim was to assess the prevalence of intestinal infections among patients suffering from IBD, when admitted to the hospital due to exacerbation of the disease.
The performed, retrospective analysis covered test results for C. difficile toxins A and B along with rectal swab cultures sampled from patients, treated in a tertiary IBD center in Poland, between 2017 and 2019. Main objective was to estimate the presence of any infection, which could imitate or co-exist along with the exacerbation of the IBD. All in all 1471 patients had microbiological tests performed, including 1112 tested for C. difficile toxins A and B; and 359 patients who had rectal swab culture. Positive test results for C. difficile toxins A and B were reported in 358 cases, positive results from rectal swab culture were confirmed altogether in case of 25 samples. As far as patients with IBD are concerned, positive results for C. difficile toxins A and B were detected in 82 cases, positive results in rectal swab culture from patients with IBD were reported in 20 cases.
Intestinal infections were reported in 14.9% of patients (102/685) with IBD symptoms. Positive test results for C. difficile toxins A and B and rectal swab cultures among patients without IBD symptoms were reported in 35.7% of cases (281/786). Intestinal superinfections may complicate the clinical picture of IBD patients, increasing the diagnostic and therapeutic burden. Appropriate early procedures are thus needed in these patients.
有多项研究评估了肠道病原体引起的感染数量,包括艰难梭菌在炎症性肠病(IBD)患者中的感染情况。我们的目的是评估因疾病加重而住院的IBD患者中肠道感染的患病率。
所进行的回顾性分析涵盖了2017年至2019年期间在波兰一家三级IBD中心接受治疗的患者的艰难梭菌毒素A和B检测结果以及直肠拭子培养结果。主要目的是估计是否存在任何可能与IBD加重同时出现或模仿其症状的感染。总共1471名患者进行了微生物检测,其中1112人检测了艰难梭菌毒素A和B;359名患者进行了直肠拭子培养。艰难梭菌毒素A和B检测结果呈阳性的有358例,直肠拭子培养结果共有25份呈阳性。就IBD患者而言,艰难梭菌毒素A和B检测结果呈阳性的有82例,IBD患者直肠拭子培养结果呈阳性的有20例。
有IBD症状的患者中,14.9%(102/685)报告有肠道感染。无IBD症状的患者中,35.7%(281/786)的艰难梭菌毒素A和B检测结果以及直肠拭子培养呈阳性。肠道二重感染可能会使IBD患者的临床症状复杂化,增加诊断和治疗负担。因此,这些患者需要采取适当的早期措施。